PRODUCTS / CNS PHARMACEUTICALS

CNS PHARMACEUTICALS

Lesvi offers one of the most comprehensive product portfolios in CNS pharmaceuticals.

Product	Indication	Dosage form	Strength
	Depression	Tablets	10 and 20 mg
Amitriptyline	Major depressive disorders and anxiety	Film-coated tablets	10, 25, 50 and 75 mg
Aripiprazole	Schizophrenia, bipolar disorder	Tablets	5, 10, 15, 20 and 30 mg
Baclofen	Spasticity	Injection	10 mg/5 ml and 10 mg/20 ml
Baclofen	Spasticity	Tablets	25 mg
Buprenorphine	Opioid dependence		0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Clonazepam	Epilepsy	Oral drops, solution	2.5 mg/ml
Clonazepam	Epilepsy	Tablets	0.5 and 2 mg
Duloxetine *	Major depressive disorders, neuropathic pain, anxiety	Gastro resistant hard capsules	30, 60, 90 and 120 mg
Eslicarbazepine acetate	Epilepsy	Film-coated tablets	800 mg
Ethosuximide	Epilepsy, absence seizures	Soft capsules	250 mg
Ethosuximide	Epilepsy, absence seizures	Oral solution	250mg / 5ml
Fampridine	Multiple sclerosis	XR tablets	10 mg
Fingolimod	Multiple sclerosis	Capsules	0.5 mg
Flupentixol decanoate	Schizophrenia	Injection	10mg/ 0,5 ml; 20mg/ ml; 40mg/ ml; 200mg / 10 ml
Lacosamide	Epilepsy	Oral solution	10 mg/ml syrup
Lamotrigine	Lamotrigine	XR tablets	25/ 50/ 100/ 200 & 300 mg
Levetiracetam	Epilepsy	Film-coated tablets	250, 500, 750 and 1000 mg
Levetiracetam	Epilepsy	Granules for oral solution	250, 500, 750, 1000 and 1500 mg
Levetiracetam	Epilepsy	Oral solution	100 mg/ml

FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.